Fifth Third Bancorp Purchases 28,699 Shares of Prestige Consumer Healthcare Inc. $PBH

Fifth Third Bancorp lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 8,130.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,052 shares of the company’s stock after purchasing an additional 28,699 shares during the quarter. Fifth Third Bancorp’s holdings in Prestige Consumer Healthcare were worth $1,722,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Norges Bank purchased a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $36,954,000. Brandes Investment Partners LP lifted its position in Prestige Consumer Healthcare by 93.2% in the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after buying an additional 292,744 shares during the last quarter. Capital Research Global Investors boosted its stake in Prestige Consumer Healthcare by 107.9% in the fourth quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock worth $34,639,000 after buying an additional 291,425 shares in the last quarter. Squarepoint Ops LLC boosted its stake in Prestige Consumer Healthcare by 316.1% in the third quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock worth $18,836,000 after buying an additional 229,311 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Prestige Consumer Healthcare by 28.4% during the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after acquiring an additional 120,965 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president directly owned 42,820 shares of the company’s stock, valued at $2,354,671.80. The trade was a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

PBH has been the topic of several research reports. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Oppenheimer cut shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group reduced their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Price Performance

PBH opened at $48.91 on Thursday. The stock’s 50 day simple moving average is $47.82 and its 200 day simple moving average is $57.04. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $77.45. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.58 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The company had revenue of $281.62 million during the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The business’s revenue for the quarter was down 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).